Literature DB >> 10679762

Serum levels of PSMA.

G P Murphy, S Su, J Jarisch, G M Kenny.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10679762     DOI： 10.1002/(sici)1097-0045(20000301)42:4<318::aid-pros10>3.0.co;2-l

Source DB:  PubMed          Journal:  Prostate        ISSN： 0270-4137            Impact factor:   4.104


× No keyword cloud information.
  4 in total

1.  Prostate-specific membrane antigen-targeted photodynamic therapy induces rapid cytoskeletal disruption.

Authors:  Tiancheng Liu; Lisa Y Wu; Clifford E Berkman
Journal:  Cancer Lett       Date:  2010-05-08       Impact factor: 8.679

Review 2.  Cholesterol as a potential target for castration-resistant prostate cancer.

Authors:  Alexis L Twiddy; Carlos G Leon; Kishor M Wasan
Journal:  Pharm Res       Date:  2010-08-04       Impact factor: 4.200

3.  Development of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer.

Authors:  Stacy E Martin; Tanushree Ganguly; Gerhard R Munske; Melody D Fulton; Mark R Hopkins; Clifford E Berkman; Margaret E Black
Journal:  Bioconjug Chem       Date:  2014-09-15       Impact factor: 4.774

4.  177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.

Authors:  Cindy J Choy; Xiaoxi Ling; Jonathan J Geruntho; Sophia K Beyer; Joseph D Latoche; Beatrice Langton-Webster; Carolyn J Anderson; Clifford E Berkman
Journal:  Theranostics       Date:  2017-04-27       Impact factor: 11.556
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.